Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase

Abstract

When covid-19 vaccines were first authorised, regulators required post-authorisation studies to tackle important uncertainties about efficacy and safety. But these studies may have little practical value unless there is greater engagement and scrutiny from the wider scientific community, argue <b>Christof Prugger and colleagues</b>